Siggi Olafsson to step down as Chief Executive

Siggi Olafsson to step down as Chief Executive

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma) today announces that Siggi Olafsson has resigned as Chief Executive Officer (CEO), and from Hikma’s Board of Directors, to pursue other opportunities. Said Darwazah, Hikma’s Executive Chairman and former CEO, will assume all CEO responsibilities, enabling Hikma to continue delivering its strategy. Siggi will remain available to the Group until he departs on 24 June 2022. Said will continue to work closely with the Executive Committee, including Hikma’s three divisional presidents, benefiting from their significant experience and strong management teams. Concurrently, Hikma’s…

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

London, England – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on current trading. Siggi Olafsson, Hikma’s CEO, said: “Hikma continues to make strategic progress, positioning the business for future growth through new product launches, continued investment in R&D, and new strategic partnerships and acquisitions, which are all driving our ability to put better health within reach, every day. Our acquisition of Custopharm, which closed last week, enhances our R&D capabilities and pipeline while further expanding our portfolio of differentiated injectable medicines. More broadly across…